PE20171246A1 - Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos - Google Patents

Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos

Info

Publication number
PE20171246A1
PE20171246A1 PE2017001208A PE2017001208A PE20171246A1 PE 20171246 A1 PE20171246 A1 PE 20171246A1 PE 2017001208 A PE2017001208 A PE 2017001208A PE 2017001208 A PE2017001208 A PE 2017001208A PE 20171246 A1 PE20171246 A1 PE 20171246A1
Authority
PE
Peru
Prior art keywords
cangrelor
solution
high purity
salt
purity cangrelor
Prior art date
Application number
PE2017001208A
Other languages
English (en)
Inventor
Panna Dutta
Far Adel Rafai
Min Ding
Rajeshwar Motheram
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55537309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171246(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PE20171246A1 publication Critical patent/PE20171246A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
    • B65D81/2069—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas in a special atmosphere

Abstract

Se refiere a una formulacion farmaceutica que comprende cangrelor de alta pureza, o una sal del mismo preparados por un metodo que comprende: (a) disolver cangrelor o una sal del mismo en un solvente para formar una primera solucion; (b) mezclar un agente de ajuste de pH con la primera solucion para formar una segunda solucion con pH alrededor de 7,0 y 9,5; y (c) remover el solvente desde la segunda solucion para producir cangrelor de alta pureza o una sal del mismo bajo las condiciones donde se logra un nivel de humedad, menor que alrededor de 2,0% en peso, donde uno o mas excipientes farmaceuticamente aceptables se agregan a la primera solucion o a la segunda solucion, o a ambas, donde el dicho cangrelor tiene un total combinado de degradantes seleccionados de oxidacion e hidrolisis de cangrelor que no excede alrededor de 1,5 % en peso de cangrelor de alta pureza y donde dichos degradantes seleccionados son impurezas. Dicha formulacion inhibe la agregacion y activacion plaquetaria
PE2017001208A 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos PE20171246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562103136P 2015-01-14 2015-01-14

Publications (1)

Publication Number Publication Date
PE20171246A1 true PE20171246A1 (es) 2017-08-24

Family

ID=55537309

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017001208A PE20171246A1 (es) 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
PE2022000692A PE20221170A1 (es) 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2022000692A PE20221170A1 (es) 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos

Country Status (13)

Country Link
US (4) US9295687B1 (es)
EP (1) EP3244900A4 (es)
KR (1) KR102440847B1 (es)
CN (2) CN107206014A (es)
BR (1) BR112017014996A2 (es)
CA (1) CA2971868C (es)
CL (1) CL2017001840A1 (es)
CO (1) CO2017006958A2 (es)
MA (1) MA41326A (es)
MX (1) MX2017009289A (es)
PE (2) PE20171246A1 (es)
RU (1) RU2733409C2 (es)
WO (1) WO2016114818A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5947316B2 (ja) * 2011-02-09 2016-07-06 ザ メディシンズ カンパニー 肺高血圧症を処置するための方法
BR112017014996A2 (pt) * 2015-01-14 2018-03-20 Chiesi Farm Spa formulações farmacêuticas e recipientes selados
BR112019022676A2 (pt) 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法
CN109781920B (zh) * 2017-11-15 2023-07-11 石药集团中奇制药技术（石家庄）有限公司 一种坎格雷洛有关物质的hplc检测方法
CN109912674A (zh) 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2108425T3 (es) 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
SE9604795D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
GB9813646D0 (en) * 1998-06-24 1998-08-26 Ciba Geigy Ag Organic compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
WO2003026642A1 (fr) 2001-09-21 2003-04-03 Sumitomo Pharmaceuticals Co., Ltd. Preparation pharmaceutique lyophilisee
DK1478339T3 (da) 2002-02-22 2008-08-25 Schering Corp Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8680052B1 (en) * 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120184504A1 (en) * 2009-10-02 2012-07-19 Strony John T "The Use of a PAR-1 Antagonist in Combination with a P2Y12 ADP Receptor Antagonist for Inhibition of Thrombosis"
EA028885B1 (ru) * 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
JP5947316B2 (ja) * 2011-02-09 2016-07-06 ザ メディシンズ カンパニー 肺高血圧症を処置するための方法
WO2013103567A2 (en) * 2012-01-04 2013-07-11 The Medicines Company Methods of blocking platelet activation during extracorporeal circulation using cangrelor
CN103860459A (zh) * 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
BR112017014996A2 (pt) * 2015-01-14 2018-03-20 Chiesi Farm Spa formulações farmacêuticas e recipientes selados

Also Published As

Publication number Publication date
RU2017127531A (ru) 2019-02-14
MA41326A (fr) 2021-04-28
MX2017009289A (es) 2017-10-11
EP3244900A1 (en) 2017-11-22
US20170304345A1 (en) 2017-10-26
KR20170103848A (ko) 2017-09-13
US9700575B2 (en) 2017-07-11
CL2017001840A1 (es) 2017-12-29
KR102440847B1 (ko) 2022-09-06
US9439921B2 (en) 2016-09-13
WO2016114818A1 (en) 2016-07-21
US20160199400A1 (en) 2016-07-14
RU2017127531A3 (es) 2019-02-14
BR112017014996A2 (pt) 2018-03-20
CO2017006958A2 (es) 2017-11-30
CN115990138A (zh) 2023-04-21
RU2733409C2 (ru) 2020-10-01
CA2971868C (en) 2023-04-04
CN107206014A (zh) 2017-09-26
US10039780B2 (en) 2018-08-07
PE20221170A1 (es) 2022-07-25
US20160296549A1 (en) 2016-10-13
CA2971868A1 (en) 2016-07-21
US9295687B1 (en) 2016-03-29
EP3244900A4 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
CL2018003452A1 (es) Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.
MX2020012041A (es) Formulacion farmaceutica.
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
AR110270A1 (es) Preparación de complejos sólidos de ciclodextrina para la administración de ingredientes farmacéuticos activos oftálmicos
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
CL2018003178A1 (es) Composición farmacéutica
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
CO2021016449A2 (es) Composiciones terapéuticas estables en solventes polares aproticos y métodos de fabricación de las mismas
CL2018001151A1 (es) Suspensión acuosa para administración oral y método para su preparación
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
CL2020001791A1 (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
CO2018000526A2 (es) Concentrado que contiene alprostadil
CO2017000354A2 (es) Desmopresina estabilizada
CL2018000559A1 (es) Métodos y composiciones para tratar condiciones asociadas con respuestas inflamatorias anormales
CL2020000356A1 (es) Composiciones farmacéuticas.